Carregant...

Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review

Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection are one of the major advances in its medical treatment. The HCV protease inhibitors boceprevir and telaprevir were the first approved DAAs in the United States, Europe, and Japan. When combined with peginterferon plus ribavi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wu, Shuang, Kanda, Tatsuo, Nakamoto, Shingo, Imazeki, Fumio, Yokosuka, Osamu
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Co., Limited 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3870547/
https://ncbi.nlm.nih.gov/pubmed/24379619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v19.i47.8940
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!